Travere Therapeutics Inc FILSPARI in IgA Nephropathy Phase 3 PROTECT Study Results Call Transcript
Good day, and welcome to the Travere Therapeutics Corporate Update Call. Today's conference call is being recorded. At this time, I would like to turn the conference call over to the Vice President of Investor Relations, Naomi Eichenbaum. Please go ahead, Naomi.
Thank you, Ruth, and thank you all for joining us today. Earlier today, we issued a press release announcing the confirmatory data from the Phase III PROTECT study of FILSPARI in IgA Nephropathy. A copy of the press release, along with the slides that we will be reviewing on today's call are available on the Investors section of our website.
Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Joining Eric will be our Chief Medical Officer, Dr. Jula Inrig and we are joined by guest speaker and key opinion leader, Dr. Brad Rovin, the Director of the Division of Nephrology at Ohio State University, Wexner Medical Center. Dr. Bill Rote, our Senior Vice President of Research and Development, will be available during the Q&A session.
Before we begin, I
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |